Onco-Summaries: Daily Oncology Updates at a Glance
03/09/2026
Phase 3 CERVINO interim analysis shows etentamig significantly improves ORR and PFS in RRMM, with IDMC recommending study unblinding (Ref)
AbbVie reported positive topline results from the Phase 3 CERVINO trial, demonstrating that etentamig (BCMA x CD3 bispecific T-cell engager) significantly improved response rates and progression-free survival in triple-class exposed (proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody) relapsed/refractory multiple myeloma (RRMM), compared to standard available therapies
The study met its dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS)
Objective response rate (ORR): 74.0% vs 45.7%
Progression-free survival: Hazard ratio 0.40, favouring etentamig
Consistent benefit across all pre-specified subgroups
1-year overall survival: 87.9% vs 72.0%
Etentamig demonstrated a potentially differentiated safety profile
Cytokine release syndrome (CRS): 28.3%, mostly grade 1; no grade ≥3 events
Infections: Grade 3/4 in 27.7% (etentamig) vs 19.2% (standard); fewer grade 5 infections with etentamig
Based on the significant benefit observed, the Independent Data Monitoring Committee (IDMC) recommended unblinding the study
AbbVie plans to discuss the Phase 3 CERVINO results with global regulatory authorities to determine next steps for etentamig
Results will be presented at upcoming International Myeloma Society Annual Meeting (Sep 23–26, 2026, Glasgow)
Comments